SCHEMBL4255042

SCHEMBL4255042

CC1=Nc2c(cc(S(=O)(=O)O)c3ccccc23)C1(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPL P40238 12/20 0.40
SENP2 Q9HC62 4/20 0.39
SENP1 Q9P0U3 4/20 0.39
SUMO2 P61956 3/20 0.39
SUMO1 P63165 3/20 0.39
SENP7 Q9BQF6 3/20 0.39
SENP3 Q9H4L4 2/20 0.39
CTRC Q99895 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
RCE1 Q9Y256 1/20 0.36
NSD2 O96028 1/20 0.36
MMP14 P50281 1/20 0.36
CASP6 P55212 1/20 0.36
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
ALOX15 P16050 1/20 0.35
ATIC P31939 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4437128 0.85 ALDH1A1 (0.35) SENP2SENP1SUMO2SUMO1SENP7
SCHEMBL4885961 0.84 TTR (0.43) MPLSENP2SUMO2SUMO1SENP7
Potassium SCHEMBL4171863 0.83 TTR (0.42) MPLSENP2SUMO2SUMO1SENP7
SCHEMBL633391 0.80 MPL (0.33) MPLSENP2SUMO2SUMO1SENP7
SCHEMBL7701818 0.77 MEN1 (0.54) MPLSENP2SENP1SUMO2SUMO1
SCHEMBL14958133 0.76 MEN1 (0.52) MPLSENP2SENP1SUMO2SUMO1
SCHEMBL101082 0.76 MYC (0.36) MEN1KMT2ACYP1A2
SCHEMBL137432 0.75 RXRA (0.30)
SCHEMBL28705484 0.71 NCOA3 (0.38) MEN1KMT2ANSD2ALDH1A1CYP1A2
SCHEMBL23961228 0.70 RXRA (0.33) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8071388-B2 Compositions and methods for biodetection by nucleic acid-templated chemistry ENSEMBLE THERAPEUTICS CORPORATION (US) 2011-12-06 US disclosed
US-8071388-B2 Compositions and methods for biodetection by nucleic acid-templated chemistry ENSEMBLE THERAPEUTICS CORPORATION (US) 2011-12-06 US disclosed
US-20090275142-A1 COMPOSITIONS AND METHODS FOR BIODETECTION BY NUCLEIC ACID-TEMPLATED CHEMISTRY ENSEMBLE THERAPEUTICS CORPORATION 2009-11-05 US disclosed
US-20090275142-A1 COMPOSITIONS AND METHODS FOR BIODETECTION BY NUCLEIC ACID-TEMPLATED CHEMISTRY ENSEMBLE THERAPEUTICS CORPORATION 2009-11-05 US disclosed
EP-2066813-A2 COMPOSITIONS AND METHODS FOR BIODETECTION BY NUCLEIC ACID-TEMPLATED CHEMISTRY Ensemble Discovery Corporation (US) 2009-06-10 EP disclosed
WO-2008054600-A2 COMPOSITIONS AND METHODS FOR BIODETECTION BY NUCLEIC ACID-TEMPLATED CHEMISTRY ENSEMBLE DISCOVERY CORPORATION (US) 2008-05-08 WO disclosed
WO-2008054600-A2 COMPOSITIONS AND METHODS FOR BIODETECTION BY NUCLEIC ACID-TEMPLATED CHEMISTRY ENSEMBLE DISCOVERY CORPORATION (US) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275142-A1 COMPOSITIONS AND METHODS FOR BIODETECTION BY NUCLEIC ACID-TEMPLATED CHEMISTRY POLRMT, NT5C3B, RNGTT MPL 4029/4885SENP2 3572/4885SENP1 3969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.